WO1990015822A1 - Anticorps monoclonal de l'epitope intracellulaire de la chaine zeta du recepteur de cellules t humaines et son procede de preparation - Google Patents

Anticorps monoclonal de l'epitope intracellulaire de la chaine zeta du recepteur de cellules t humaines et son procede de preparation Download PDF

Info

Publication number
WO1990015822A1
WO1990015822A1 PCT/US1990/003403 US9003403W WO9015822A1 WO 1990015822 A1 WO1990015822 A1 WO 1990015822A1 US 9003403 W US9003403 W US 9003403W WO 9015822 A1 WO9015822 A1 WO 9015822A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
monoclonal antibody
permeabilized
lymphocytes
antibody
Prior art date
Application number
PCT/US1990/003403
Other languages
English (en)
Inventor
Paul J. Anderson
Stuart F. Schlossman
Original Assignee
Dana-Farber Cancer Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana-Farber Cancer Institute filed Critical Dana-Farber Cancer Institute
Publication of WO1990015822A1 publication Critical patent/WO1990015822A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to monoclonal antibodies, and specifically to monoclonal antibodies to lymphocytes.
  • Monoclonal antibodies reactive with lymphocyte surface structures are useful as therapeutic and diagnostic agents and as reagents in studies of lymphocyte biology.
  • a prominent structure on peripheral blood T lymphocytes is the T cell antigen receptor complex.
  • the receptor portion of the complex consists of primarily extracellular, variable, clone-specific heterodimers (composed of the subunit proteins alpha, beta, gamma, or delta) which determine the specificity of the receptor and function as the binding site for antigen.
  • the heterodimers are noncovalently associated with the proteins of the CD3 complex - gamma, delta, epsilon, zeta, and eta. It is believed that the proteins of the CD3 complex, which have primarily invariant regions, act as intracellular transducers of the ligand- binding signals.
  • the individual proteins of the complex are synthesized intracellularly, and the complex is assembled and then transported to the plasma membrane.
  • the zeta chain whose nine amino acid extracellular domain is identical in man and mouse, is synthesized in rate limiting amounts and appears to play a unique role in intracellular targeting and assembly and the efficient expression of the complex on the cell surface. In the absence of zeta, 95% of the receptor complexes are rapidly transported to and degraded in liposomes. A low expression of the CD3 zeta chain can lead to clinical symptoms of immunodeficiency.
  • Monoclonal antibodies reactive with a particular antigen are prepared by standard techniques: immunizing a mammal, e.g., a mouse, with the antigen; fusing splenocytes from the immunized mammal to myeloma cells for the production of hybridomas; obtaining viable clones of the hybridomas; and screening the clones for their reactivity with the antigen (e.g., by flow cytometric analysis) .
  • the invention features, in one aspect, a monoclonal antibody of class IgG, which antibody selectively binds to permeabilized T cells but not to permeabilized B cells nor to unpermeabilized T cells.
  • the monoclonal antibody is produced by a hybridoma formed by fusion of cells from a mammalian myeloma line (specifically NS-1 myeloma cells) and spleen cells from a mammal (specifically a Balb/c mouse) previously immunized with permeabilized human T cells (specifically from Ficoll purified peripheral blood mononuclear cells) ; the antibody, TIA-2, recognizes a T cell restricted 32 d homodi er, a dimer of the zeta chain of the T cell receptor complex.
  • the invention features a method of screening a population of monoclonal antibodies for a monoclonal antibody that selectively binds to permeabilized but not unpermeabilized lymphocytes; the method includes the steps of stabilizing a population of lymphocytes by contacting the cells with a mild fixative; permeabilizing the cells by contacting them with a mild glycosidic detergent; contacting a population of monoclonal antibodies with the stabilized, permeabilized cells; contacting the same population of monoclonal antibodies with unpermeabilized cells; and selecting a monoclonal antibody that reacts with the permeabilized lymphocytes but not with the non-permeabilized lymphocytes.
  • the lymphocytes are T cells; the fixative is formaldehyde at a concentration of from 0.005 - 0.1%, preferably 0.01%; and the mild glycosidic detergent is digitonin at 1 to 100 ⁇ g/ml, preferably 10 ⁇ g/ml.
  • the invention features a method of determining the state of T cell activation of a patient that involves contacting serum, urine, or circulating peripheral blood cells from the patient with a monoclonal antibody that recognizes the zeta chain of the T cell receptor complex (e.g., TIA-2) and measuring the extent of binding of the antibody with the zeta chain; to determine the extent of T cell infiltration of a specific tissue, a fixed tissue section is contacted with the monoclonal antibody.
  • a monoclonal antibody that recognizes the zeta chain of the T cell receptor complex (e.g., TIA-2) and measuring the extent of binding of the antibody with the zeta chain; to determine the extent of T cell infiltration of a specific tissue, a fixed tissue section is contacted with the monoclonal antibody.
  • the invention provides a way of screening a population of monoclonal antibodies for an antibody that binds specifically to an intracellular target as opposed to a surface molecule of a specific lymphocyte population.
  • the specific monoclonal antibody described, TIA-2 was unlikely to be isolated by screening methods that analyzed only for antibodies to cell surface molecules as the bulk of the zeta protein chain resides intracellularly.
  • TIA-2 can be used as a rapid diagnostic reagent for the assessment of the state of lymphocyte activation, for example in patients with autoimmune diseases such as systemic lupus erythematosas. rheumatoid arthritis, vasculitis, and polymyositis. In patients who are recent allograft recipients, T cell activation could indicate imminent graft rejection.
  • TIA-2 can be used as a stain to locate lymphocytes in fixed tissues. TIA-2 is also likely to be a valuable research reagent in determining the specific role of the zeta chain in T cell activation.
  • Figs, l and 2 are autoradiograms of SDS polyacrylamide gels.
  • Monoclonal antibody TIA-2 selectively recognizes permeabilized but not unpermeabilized T lymphocytes and is directed at an intracellular epitope of the T cell receptor zeta chain.
  • TIA-2 was isolated by the following procedure.
  • Hybridomas suitable for screening for production of antibodies reactive with intracellular antigens were prepared by immunizing 6 week old Balb/c mice with permeabilized T lymphocytes (25-30 x 10 ) at 21 day intervals over a 9-12 week period.
  • the immunogen was prepared using Ficoll purified peripheral blood mononuclear cells obtained from plateletpheresis residues that were rosetted with sheep erythrocytes (Lay et al. , Nature 300;267(1971) ) . Purified T lymphocytes were washed three times in PBS, resuspended at 5 x 10 cells/ml and permeabilized by the addition of digitonin (10 ⁇ g/ml) for 5 minutes on ice. The adequacy of permeabilization was monitored by determining trypan blue uptake, which was typically greater than 90%.
  • Permeabilized lymphocytes were pelleted, resuspended at 25-30 x 10 cells/ml in sterile PBS and injected intraperitoneally into Balb/c mice. Splenocytes from immunized mice were fused to NS-1 myeloma cells for the production of hybridomas (Kohler et al.. Nature
  • T lymphocytes purified by sheep erythrocyte rosetting were first stabilized by mild fixation with 0.01% formaldehyde in PBS for 20 min. on ice.
  • the lymphocytes could be stabilized by any other mild fixative, e.g., glutaraldehyde at 0.1- 1%.
  • any mild detergent having the properties of digitonin would be a suitable permeabilizing agent.
  • TIA-2 Monoclonal antibodies that selectively reacted with intracellular T cell specific structures were selected by screening the hybridoma supernatants on digitonin treated T cells and B cells as well as on native T cells.
  • TIA-2 was one such monoclonal antibody selected. The specificity of binding of TIA-2 is indicated in the following table:
  • T4C1 clone +++ >95%)
  • T4T8C1 clone +++ >95%)
  • TIA-2 Intracellular epitope on the zeta chain of the T cell receptor complex.
  • Peripheral blood T lymphocytes that had been permeabilized by the method described previously were radioiodinated using lactoperoxidase.
  • immunoprecipitates were formed using TIA-2, separated on SDS polyacrylamide gels, and subjected to autoradiography. As shown in Fig. 1, immunoprecipitates formed using TIA-2 (lanes 2 and 5) included a prominent band at 32 kd that was reduced to 16 kd in the presence of 2-mercaptoethanol.
  • TIA-2 binds to a 32 kd disulfide linked homodimeric structure, the same structure as that of the zeta chain.
  • TIA-2 is a highly sensitive probe for T cells in fixed tissues; therefore, TIA-2 can be used to monitor the extent of T cell infiltration into specific tissues.
  • a detection of an increase of zeta chain in a speciman of a biological fluid from a patient, e.g., serum or urine, or a decrease in surface zeta chain in circulating peripheral blood T lymphocytes would indicate T cell activation, e.g. , in a patient with an autoimmune disease.
  • the detection of T cell activation could indicate imminent graft rejection.
  • lymphocytes other than T cells can be fixed and permeabilized by the method described above and then used to screen a population of monoclonal antibodies prepared against the specific lymphocyte under analysis.
  • fixed and permeabilized lymphocytes of any type could be analyzed for selective binding to a monoclonal antibody by an enzyme-linked ELIZA assay instead of by flow cytometry.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un anticorps monoclonal de la classe IgG se lie sélectivement à des cellules T perméabilisées mais non à des cellules T non perméabilisées. L'anticorps monoclonal TIA-2 se lie à un épitope intracellulaire de la chaîne zêta du complexe récepteur des cellules T. Selon un procédé d'analyse d'une population d'anticorps monoclonaux afin de détecter un anticorps monoclonal qui se lie sélectivement à des lymphocytes perméabilisés mais non à des lymphocytes non perméabilisés, on stabilise une population de lymphocytes en mettant les cellules en contact avec un fixateur doux, on perméabilise les cellules en les mettant en contact avec un détergent glucosidique doux, on met la population d'anticorps monoclonaux en contact avec les lymphocytes perméabilisés stabilisés, on met en contact la population d'anticorps monoclonaux avec des lymphocytes non perméabilisés et on sélectionne un anticorps monoclonal qui réagit avec les lymphocytes perméabilisés mais non avec les lymphocytes non perméabilisés.
PCT/US1990/003403 1989-06-15 1990-06-15 Anticorps monoclonal de l'epitope intracellulaire de la chaine zeta du recepteur de cellules t humaines et son procede de preparation WO1990015822A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36688189A 1989-06-15 1989-06-15
US366,881 1989-06-15

Publications (1)

Publication Number Publication Date
WO1990015822A1 true WO1990015822A1 (fr) 1990-12-27

Family

ID=23444973

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/003403 WO1990015822A1 (fr) 1989-06-15 1990-06-15 Anticorps monoclonal de l'epitope intracellulaire de la chaine zeta du recepteur de cellules t humaines et son procede de preparation

Country Status (1)

Country Link
WO (1) WO1990015822A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0436400A1 (fr) * 1990-01-05 1991-07-10 Dana Farber Cancer Institute Antigène intracellulaire d'une sous-population de T-lymphocytes CD9-positives et un anticorps monoclonal réagissant avec cela
US5340935A (en) * 1990-01-05 1994-08-23 Dana-Farber Cancer Institute, Inc. DNAS encoding proteins active in lymphocyte-medicated cytotoxicity
WO2000003016A1 (fr) * 1998-07-10 2000-01-20 Connex Gmbh Reactif immunologique capable d'interagir specifiquement avec le domaine extracellulaire de la chaine zeta humaine

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CELL, Vol. 52, issued 15 January 1988, "Failure to synthesize the T cell CD3 - zeta chain: structure and function of a partial T cell receptor complex", (SUSSMAN et al.), pp. 85-95, see p. 93. *
NATURE, Vol. 324, issued 04 December 1986, "A new subunit of the human T cell antigen receptor complex", (WEISSMAN et al.), pp. 480-482, see entire document. *
NEW ENGLAND JOURNAL OF MEDICINE, Vol. 319, No. 18, issued 03 November 1988, "Familial defect in the surface expression of the T cell receptor, CD3 complex", (ALARCON et al.), pp. 1203-1208, see pp. 1203, 1207-8. *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, Vol. 77, No. 6, issued June 1980, "The cytoskeleton of digitonin-treated rat hepatocytes", (FISKUM et al.), pp. 3430-3434, see entire document. *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, Vol. 85, issued December 1988, "Molecular cloning and chiomosoman localization of the human T-cell receptor zeta chain: distinction from the molecular CD3 complex", (WEISSMAN et al.), pp. 9709-9713, see p. 9710. *
THE JOURNAL OF IMMUNOLOGY, Vol. 134, No. 2, issued February 1985, "Co-expression of an epitope on human free k-light chains and on a cytoplasmic component in activated T cells", (WALKER et al.), pp. 1059-1064, see pp. 1059, 1060. *
WEIR, D.M., "Handbook of experimental immunology", Volume 4, published 1986 by BLACKWELL SCIENTIFIC PUBLICATIONS (OXFORD), see pages 108.1-108.9. *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0436400A1 (fr) * 1990-01-05 1991-07-10 Dana Farber Cancer Institute Antigène intracellulaire d'une sous-population de T-lymphocytes CD9-positives et un anticorps monoclonal réagissant avec cela
US5298407A (en) * 1990-01-05 1994-03-29 Dana-Farber Cancer Institute, Inc. DNA encoding a protein active in lymphocyte-mediated cytotoxicity
US5340935A (en) * 1990-01-05 1994-08-23 Dana-Farber Cancer Institute, Inc. DNAS encoding proteins active in lymphocyte-medicated cytotoxicity
US5837811A (en) * 1990-01-05 1998-11-17 Dana-Farber Cancer Institute, Inc. Proteins active in lymphocyte-mediated cytotoxicity
WO2000003016A1 (fr) * 1998-07-10 2000-01-20 Connex Gmbh Reactif immunologique capable d'interagir specifiquement avec le domaine extracellulaire de la chaine zeta humaine

Similar Documents

Publication Publication Date Title
Myones et al. Neutrophil and monocyte cell surface p150, 95 has iC3b-receptor (CR4) activity resembling CR3.
Rojo et al. Physical association of CD4 and the T-cell receptor can be induced by anti-T-cell receptor antibodies.
US5644033A (en) Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
US4676980A (en) Target specific cross-linked heteroantibodies
US5340921A (en) Γ, δT cell receptor and methods and detection
Spertini et al. Induction of human T cell proliferation by a monoclonal antibody to CD5.
Young Jr et al. Staphylococcal protein A binding to the Fab fragments of mouse monoclonal antibodies.
Hua et al. Monoclonal antibodies against an H-2Kb-specific cytotoxic T cell clone detect several clone-specific molecules.
Michaelsen et al. Antibody dependent cell-mediated cytotoxicity induced by chimeric mouse-human IgG subclasses and IgG3 antibodies with altered hinge region
Bernard et al. AT cell surface molecule different from CD2 is involved in spontaneous rosette formation with erythrocytes.
US5631349A (en) Chimeric monoclonal antibodies recognizing human interleukin-2-receptor
EP0203403B1 (fr) Cellule T clonée capable de reconnaître des tumeurs et un récepteur antigénique de cellule T
Klein et al. Binding site of human IgG subclasses and their domains for Fc receptors of activated murine T cells
Diamond et al. Site of binding of mouse IgG2b to the Fc receptor on mouse macrophages.
Würzner et al. Blood dendritic cells carry terminal complement complexes on their cell surface as detected by newly developed neoepitope-specific monoclonal antibodies.
Trapani et al. Description of a mouse monoclonal anti-HLA-B27 antibody HLA-ABC-m3
Walter et al. Generation and characterization of a novel adhesion function blocking monoclonal antibody recognizing both rat and mouse E-selectin
Tumas et al. Monoclonal antibodies to the equine CD2 T lymphocyte marker, to a pan-granulocyte/monocyte marker and to a unique pan-B lymphocyte marker
AU705010B2 (en) Human antibodies to t-cell receptor peptides and methods for their preparation
WO1991015232A1 (fr) Fragment cd43 se liant a des autoanticorps produits par des personnes infectees par le vih
WO1990015822A1 (fr) Anticorps monoclonal de l'epitope intracellulaire de la chaine zeta du recepteur de cellules t humaines et son procede de preparation
JP2831852B2 (ja) ヒト胸腺皮質細胞上に発現する細胞表面タンパク質及びその利用
US5441871A (en) Monoclonal antibody reactive to human leukemia and lymphoma cells and methods of using same for diagnosis and treatment
Hoffmann et al. Characterization of a soluble form of CD58 in synovial fluid of patients with rheumatoid arthritis (RA)
US5286653A (en) Method for detecting the γ,δ T cell receptor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

NENP Non-entry into the national phase

Ref country code: CA